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Abstract
Background: The dog is frequently used as a model for hematologic human diseases. In this study the suitability
of nine potential reference genes for quantitative RT-PCR studies in canine whole blood was investigated.
Findings: The expression of these genes was measured in whole blood samples of 263 individual dogs,
representing 73 different breeds and a group of 40 mixed breed dogs, categorized into healthy dogs and dogs
with internal and hematological diseases, and dogs that underwent a surgical procedure. GeNorm analysis revealed
that a combination of 5 to 6 of the most stably expressed genes constituted a stable normalizing factor. Evaluation
of the expression revealed different ranking of reference genes in Normfinder and GeNorm. The disease category
and the white blood cell count significantly affected reference gene expression.
Conclusions: The discrepancy between the ranking of reference genes in this study by Normfinder and Genorm
can be explained by differences between the experimental groups such as “disease category” and “WBC count”.
This stresses the importance of assessing the expression stability of potential reference genes for gene experiments
in canine whole blood anew for each specific experimental condition.
Findings
Context
The dog is frequently used as an experimental model
for hematologic human diseases [1]. The use of dogs
can be explained by the fact that the dog offers a vari-
ety of spontaneous and experimental models of hema-
tologic diseases. Recent examples are the use of canine
hemophilia A [2] and B models [3,4], and the Canine
Leukocyte Adhesion Deficiency model (CLAD) [5,6] in
gene therapy experiments [2-8], and pharmacological
experiments in leukopenic dogs [7] and in dogs with
CLAD [8]. The larger size of dogs compared to small
rodent models allows similar surgical procedures in
humans as in dogs, and permits in most cases ade-
quate acquisition of diagnostic samples. The dog has
been a longstanding model for bone marrow and more
recently for stem cell transplantations [9,10]. Anticoa-
gulant therapy has been tested extensively in canine
cardiac surgery models [11,12]. Also the pathogenesis
and therapy of acquired disorders of hemostasis such
as disseminated intravascular coagulation [13], throm-
bosis [14,15], and hemolytic uremic syndrome [16]
have been investigated in canine models.
A disadvantage of the canine model compared to
human or small rodent models is the limited availability
of antibodies against canine intra- and extracellular pro-
teins such as CD markers. At least 350 CD markers are
defined in humans [17,18], while in the first and to date
only workshop on canine leukocyte antigens only 127
antibodies were investigated [19]. A more recent study
tested cross species reactivity with commercially avail-
able anti human CD molecules against canine leuko-
cytes, erythrocytes and platelets and identified only a
limited number of 51 cross reacting mAbs [20]. In con-
trast to the limited knowledge of canine CD markers,
the canine genome has been sequenced in total [21].
Therefore most molecular tools can be readily applied
in dog research. Real-time quantitative reverse transcrip-
tase PCR (Q-PCR) offers an accurate and sensitive alter-
native to quantification of gene expression [22] and for
that reason is well suited to study biological processes
and has also many practical clinical applications. Q-PCR
has already been shown to be a valuable adjunct in
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immunophenotyping and the quantification of residual
disease in leukemia [23-26].
Multiple variables need to be controlled when per-
forming a Q-PCR, such as the quality of RNA after iso-
lation, the input amount and quality of mRNA and
cDNA reaction efficacy, efficiency of the enzymatic reac-
tions, and cell to cell variability in translational activity.
One of the solutions to control for the internal variation
that affect the outcome of the Q-PCR reaction is the
use of reference genes as an internal standard [22,27].
Reference genes are selected based on the supposition
that their expression is stable in all cells regardless of
the tissue or individual [28]. It has been proven, how-
ever, that many genes essential for basic cellular
mechanisms and hitherto thought to have a stable
expression throughout the organism actually did not
comply with this assumption [29-35]. Therefore, it is
essential that the assumption of stable expression of
potential reference genes is verified for each experimen-
tal set up [28,36-38].
In this study we investigated the suitability of nine fre-
quently used reference genes in Q-PCR for the use as
reference genes in a quantitative real-time PCR in
canine whole blood and the influence of dog breed, sex,
disease category and disease duration on the Cq of these
genes was assessed.
Methods
Blood sample collection
Between September 2007 and October 2008 canine
blood samples (n = 263) were taken from dogs sub-
mitted to the intensive care unit of the small animal
hospital of the Veterinary Faculty of the Utrecht Univer-
sity (The Netherlands) from healthy control dogs (n = 6;
group A) and dogs categorized into three disease
groups. Group B (n = 85) had surgery within the pre-
ceding 24 hours, group C (n = 107) were dogs with mis-
cellaneous internal diseases, and group D (n = 65) had
hematologic disease (disseminated intravascular coagula-
tion (n = 27), systemic inflammatory disease (n = 24),
and immunemediated hemolysis (n = 14).
The 263 dogs represented 73 different breeds and a
group of mixed breed dogs (n = 40). Breeds that were
represented by at least 5 dogs were the Labrador retrie-
ver (n = 30), Golden retriever (n = 18), Jack Russell ter-
rier (n = 10), (Bordeaux dog (n = 9), Dachshund n = 9),
Boxer (n = 7), German shepherd and German pointer
(n = 6), and the Bernese mountain dog, Beagle, English
Cocker spaniel, and the Bearded collie were all repre-
sented by 5 dogs. There were 42 female dogs, 91
castrated female dogs, 78 males, and 47 castrated male
dogs. Of 3 dogs the sex was not noted in the file. The
mean age of the dogs was 6.5 years (range 12 weeks to
14 years, SD 3.5 years).
Two milliliters of EDTA-anticoagulated blood were
collected from each dog on the day of admittance and
during the period the dog was hospitalized consecutive
samples were taken at least 24 hours apart.
From 99 of the dogs, a second sample was available
(37 of group B, 30 of group C, 32 of group D), and in,
respectively, 34 dogs a third (10 of group B, 6 of group
C, 18 of group D), and in 13 dogs a fourth sample (4 of
group B, 3 of group C, 6 of group D) was available.
All procedures were approved by and performed
according to the ethical committee as required under
Dutch legislation.
RNA isolation and cDNA synthesis
In view of the large sample number but small samples
size, the RT-reaction was performed only once. The
MIQE guidelines, however, suggest to perform it twice
[39,40]. From each dog duplo samples were prepared by
mixing 0.5 ml EDTA-anticoagulated blood with 1.3 ml
RNAlater (Ambion, Applied Biosystems, Foster City,
California, USA). Samples were stored at -20°C. Total
RNA was extracted from the samples using the Ribo-
Pure™-Blood kit reagent (Ambion, Applied Biosystems,
Foster City, USA) according to the manufacturer’s
instructions including a DNAse treatment to destroy
contaminating genomic DNA and minimize the effect of
pseudogenes. The RNA concentration was determined
spectrophotometrically by the NANOdrop 1000 Isogen
Life Science, IJsselstein, The Netherlands). Bio-Rad
iScript, containing both oligodT and random hexamer
primers, was used to synthesize cDNA from 1 μg of
total RNA according to the manufacturer’s instructions
(iSCRIPT, Bio-Rad, Veenendaal, The Netherlands).
Primer design and testing
The selection and testing of candidate reference genes
was based on gene targets that have already been used
in human and veterinary research, and have been pre-
viously reported [41,42]. Nine genes representing various
biological processes (GAPDH, SRPR, HPRT, B2M,
GUSB, HNRNPH, RPL8, RPS5, RPS19) were selected as
candidate reference genes. Their full names, GenBank
accession numbers, and location in the canine chromo-
some are given in Table 1. The primers that were used,
location of these primers within the gene, and the length
of the resulting amplicon are given in Table 2. Primers
were developed based upon known canine sequences
(Ensembl, http://www.ensembl.org and GenBank, http://
www.ncbi.nih.gov/genbank/index.html). The primers
were designed with Oligo Explorer 1.1 (http://www.gen-
elink.com/tools/gl-downloads.asp). The specificity and
uniqueness of each primer were verified with the Basic
Local Alignment Search tool expecting return of Gen-
bank accession numbers of candidate reference genes
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only (http://www.genelink.com/tools/gl-downloads.asp).
All primer pairs, except for GAPDH, were intron span-
ning. The PCR reaction was optimized for the primers.
Optimal Tm values ranged from 55°C for RPL8 to
62.5°C for RPS5 (Table 2). Amplification efficiency cal-
culations from all standard curves were between 93.9
and 106.7%. All no template controls were negative.
Quantitative PCR
Q-PCR was done with the DNA-binding SYBR green
using the BioRad iCycler MyiQ Real-Time PCR Detec-
tion System (BioRad, Hertfordshire, United Kingdom)
according to the manufacturer’s instructions. Primers
(Eurogentec, Maastricht, The Netherlands) had a final
concentration of 400 nM each. One microliter of cDNA
was used per Q-PCR reaction. Optimal Tm was deter-
mined previously [41,42]. Reactions with a Tm less than
58°C started with 5 min at 95°C, followed by 40 cycles
of 20 s at 95°C, 30 s at Tm, and 30 s at 72°C. This reac-
tion was continued by a melting curve, stepwise increas-
ing temperature each 15 s by 0.5°C, ranging from 60 to
95°C. In case the Tm was 58°C or higher, the elongation
step at 72°C was omitted and Tm remained 30 s. Analy-
sis of Q-PCR results were performed with iQ™5
software (Biorad, Veenendaal, The Netherlands) based
on the mean Cq obtained from the duplo of each
Q-PCR reaction.
Analysis gene expression
Firstly, the influence of experimental condition such as
disease category and duration, sex, leukocyte count on
potential reference gene expression were determined.
For each potential reference gene a comparison of the
mean Cq values obtained at the first sampling for the
disease groups A, B, C, and D, and sex was performed
using the ANOVA. To determine if the differences in
Cq’s for the nine potential reference genes were due to
changes in expression levels over time an ANOVA was
used. Using a forward selection process, two explanatory
variables, “dog” and “sample number”, were introduced
as factors in the ANOVA. The result variable was the
observed Cq value. The resulting models were compared
using the likelihood ratio test.
The mean Cq values for dogs with a leukocyte count
within the reference range (4.5 - 14.6 *109/l) were com-
pared to mean Cq’s of dogs with a leukocyte count
above 30 *109/l, which can be considered a clinically
relevant leukocytosis. If a significant difference was
Table 1 Abbreviations, GenBank Accession numbers, names, and chromosomal location of canine candidate reference
genes evaluated
Gene GenBank Accession No. Name Chromosomal location in Canis familiaris
RPS19 XM_533657 Ribosomal protein S19 Chromosome 1
RPL8 XM_532360 Ribosomal protein L8 Chromosome 13
RPS5 XM_533568 Ribosomal protein S5 Chromosome 1
GUSB NM_001003191 Beta-Glucuronidase Chromosome 6
B2M XM_535458 Beta-2-microglobulin Chromosome 30
HNRNPH XM_538576 Heterogeneous nuclear ribonucleoprotein H Chromosome 11
HPRT AY283372 Hypoxanthine phosphoribosyltransferase 1 Chromosome X
GAPDH NM_001003142 Glyceraldehyde-3-phosphate dehydrogenase Chromosome X
SRPR X03184 Signal recognition particle receptor Chromosome 5
Table 2 Primer sequences, exon locations, amplicon size, and optimal melting temperature of canine candidate
reference genes
Gene Forward 5’ ®3’* Exon(s) Reverse 5’ ® 3’ Exon(s) Product length (bp) Tm (°C)
RPS19 CCTTCCTCAAAAA/GTCTGGG 2/3 GTTCTCATCGTAGGGAGCAAG 3 95 61.0
RPL8 CCATGAAT/CCTGTGGAGC 4/5 GTAGAGGGTTTGCCGATG 5 64 55.0
RPS5 TCACTGGTGAG/AACCCCCT 2/3 CCTGATTCACACGGCGTAG 3 141 62.5
GUSB AGACGCTTCCAA/GTACCCC 3/4 AGGTGTGGTGTAGAGGAGCAC 4 103 62.0
B2M TCCTCATCCTCCTCGCT 1 TTCTCTGCTGGGTGTCG 2 85† 61.2
HNRNPH CTCACTATGATCCACCACG 5 TAGCCTCCATAAC/CTCCAC 5/6 151 61.2
HPRT AG/CTTGCTGGTGAAAAGGAC 5/6 TTATAGTCAAGGGCATATCC 7 114‡ 56.0
GAPDH TGTCCCCACCCCCAATGTATC 2 CTCCGATGCCTGCTTCACTACCTT 2 100 58.0
SRPR GCTTCAGGATCTGGACTGC 5/6 GTTCCCTTGGTAGCACTGG 6 81 61.2
* If a primer is located on two exons, the junctions are shown with a dividing forward slash (/).
† Genomic product size would be approximately 3.6 kb.
‡ Genomic product size would be approximately 300 bp.
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observed, a pair wise comparison was made using the
T-test with Holmes correction for multiple comparisons.
Secondly, a linear mixed effects model was used to
assess the significance as well as the magnitude of the
effect of leukocyte count on Cq per dog, with the mean
Cq as response variable, the natural logarithm of the
“leukocyte count” as explanatory variable, and the “dog”
as random effect. Similarly, a linear mixed effects model
was used to determine if the leukocytes count changed
over time per dog. An ANOVA was used to compare
the leukocyte counts in the disease groups A, B, C and
D. A linear model was used to examine the relationship
of the Cq with the variables “disease category” and the
natural logarithm of the “leukocyte count”.
All statistical analyses were performed in R (http://
www.r-project.org). P below 0.05 was considered signifi-
cant in all analyses.
To determine the ranking of best performing reference
genes in whole blood the stability of expression of the
candidate reference genes was calculated using the GeN-
orm [27] and Normfinder [43] algorithm software. The
gene expression stability calculations in this study were
performed on the first sample that was taken when the
dog entered the study.
In Genorm the expression ratio for each pair of candi-
date reference genes is calculated for the data array of
all samples and log2-transformed. “M” is the arithmetic
mean of the pair wise variation measured as the
standard deviation of thus obtained values. A low “M”
indicates little variation in expression of the two genes.
Then the optimal number of control genes for normali-
sation is determined. Firstly, the normalisation factor is
calculated based on the two reference genes with the
lowest “M"-values. Secondly, the contribution of an
additional candidate reference gene to the variance of
the normalisation factor ratios is calculated by the step-
wise introduction of the reference genes following the
earlier established ranking order of their “M"-values.
Shortly, Normfinder makes use of a mathematical
model to describe the expression values measured by
RT-PCR, separate analysis of the sample subgroups, and
estimation of both the intra- and the intergroup expres-
sion variation, and finally calculates a candidate gene
“Stability Value.”
Results
Expression of candidate reference genes
The range and median Cq values of the first sample that
was taken in the dogs in the disease groups A, B, C and
D (described above) are depicted in Figure 1. There was
a significant difference between the mean Cq’s measured
in groups B and C for RPL8, RPS19, B2M and
HNRNPH, the differences being 0.35, 0.39, 0.44, and
0.35 Cq, respectively. The difference between groups B
and D for B2M was 0.51 Cq, and between A and C for
GAPDH it was 1.1 Cq (Figure 1). “Sample number”
did not significantly determine the Cq, except for SRPR
(p = 0.013), nor did “sex” and “breed”.
Next the leukocyte count was examined. The leuko-
cyte counts of disease group A was within the reference
range (median 8.6, range 6.6 - 12.5*109/l). The leukocyte
counts of disease groups B (median 15.9, range 3.8 -
107.8*109/l) and C (median 16.8, range 2.1 - 44.6*109/l)
were statistically significant from group D (median 22.6,
range 4.8 - 175.9*109/l) (P = 1.9*10-7 and 7.8*10-6
respectively). The linear mixed effects model revealed
that “leukocyte count” did not significantly change
between sequential samples taken during the course of
the disease.
The linear mixed effects model that included only
“leukocyte count” as explanatory variable for the Cq was
not significant for SRPR, HNRNPH, and GUSB. The
other 6 potential reference genes (B2M, RPL8, RPS19,
RPS5, GAPDH, and HPRT) had significant changes in
Cq, ranging from -0.87 to 1.28 for an a ten fold increase
in leukocyte count. A significant difference between the
Cq’s of dogs with a leukocyte count within the reference
range and dogs with a leukocyte count above 30 *109/l
was found for RPS19, RPL8, RPS5, B2M, and HPRT.
Additionally, in this analysis, GAPDH, was identified as
the fourth of the nine reference genes that was not sig-
nificantly influenced by leukocyte count (Table 3).
Figure 1 Real-time PCR cycle threshold numbers (Cq values)
for nine potential reference genes in 4 disease categories
(n = 263) . Real-time PCR cycle threshold numbers (Cq values) are
plotted for nine potential reference genes. Group A included 6
healthy dogs, group B 85 dogs within 24 hours after a surgical
procedure, group C 107 dogs with miscellaneous internal diseases,
and group D 65 dogs with hematologic diseases. Statistically
significant differences between mean Cq of the disease categories
are depicted.The boxes represent the two middle quartiles with
medians. Whiskers delineate the range.
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The linear model that included both “leukocyte count”
and the “disease category” as explanatory variables for
the Cq was statistically significant for both RPS5 and
B2M. “Disease category” was the statistically significant
factor determining Cq in the case of SRPR, HNRNPH,
GUSB and GAPDH and “leukocyte count” in the case of
RPS19, RPL8, and HPRT.
In order to identify the genes that had the least vari-
able expression, expression stability was evaluated using
GeNorm and Normfinder software analysis. The pair
wise variation between the normalisation factors calcu-
lated by GeNorm steadily decreased after inclusion of
the fourth additional reference gene and falls below the
cut-off of 0.15 that is suggested by the GeNorm pro-
gramme after adding the fifth gene [27] (Figure 2). The
ranking of the potential reference genes by GeNorm and
Normfinder is given in Table 4.
Discussion
Studying gene expression by the sensitive, specific, and
accurate technique of quantitative RT-PCR has become
increasingly important in biomedical research. The goal
of this study was to select reference genes that can be
used as a normaliser when studying gene transcription
in canine blood cells. Nine genes that are either conven-
tionally used as reference genes or were shown to have
a stable expression in hematopoietic cells or whole
blood were chosen as potential candidate reference
genes in this study [36,41,42,44,45] (Table 1). Even
genes that regulate basic cellular tasks have been shown
to be regulated [29-35,46]. To exclude that the expres-
sion of the potential reference genes was influenced by
the experimental conditions in our study we investigated
the effect of several parameters such as disease category,
disease duration, and leukocyte count. Additionally, two
software algorithms, respectively, Normfinder [43] and
GeNorm [27], were used to calculate gene expression
stability and help select the combination of reference
genes that provides the most stable normalizer for a
specific experimental situation.
Whole blood RNA originating from all cells present in
the peripheral blood, as opposed to RNA derived from a
cell sorting procedure, was used for the reverse tran-
scriptase reaction in this study. To correct for the leuko-
cyte count reaction was performed on a fixed amount of
starting RNA. The influence of a disproportionate
increase of a subset of the leukocytes on reference gene
expression is not countered by this. This disadvantage
has to be weighed against the advantage of being able to
investigate simultaneously the expression of multiple
Table 3 Relation of Cq and white blood cell count
Gene Cq change for 10 fold increase in WBC count p WBC within reference range WBC > 30*109/l Difference p
Mean Cq SD Mean Cq SD
RPS19 0.92 0 17.35 0.82 17.90 1.31 0.56 0.002
RPL8 0.52 0.006 19.20 0.67 19.52 1.14 0.32 0.026
RPS5 1.06 0 18.30 0.86 19.01 1.61 0.71 0.0009
GUSB - 0.07 0.75 21.09 0.97 21.08 1.47 -0.01 0.93
B2M 1.28 0 15.85 0.86 16.58 1.74 0.73 0.0006
HNRNPH - 0.09 0.68 22.40 0.86 22.20 1.02 -0.20 0.19
HPRT - 0.87 0 21.14 0.93 20.71 1.03 -0.43 0.01
GAPDH - 0.51 0.023 14.87 0.97 14.80 0.96 -0.07 0.38
SRPR 0.10 0.70 18.30 1.09 19.01 1.51 0.03 0.91
• WBC = White Blood Cell Count.
Change in Cq is given for a ten fold increase in WBC count, mean Cq and SD for dogs with WBC count in the reference range and for dogs with a leukocytosis
with a WBC > 30*109/l.
Figure 2 Pairwise variations between 2 sequential
normalization factors including an increasing number of
potential reference genes . To determine the optimal number of
reference genes, first the geometric mean of the expression of the
previously ranked genes was calculated and then pair wise
variations between sequential normalisation factors were calculated.
Using the cut-off recommended by GeNorm of 0.15 the optimal
number of reference genes for the data set in this study would be
at least 5.
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genes originating from distinct cell types. And, addition-
ally, against the fact that cell sorting procedures have
been shown to affect gene expression. Five to nine fold
up regulation of cytokine expressions were seen after
density gradient separation of leukocytes [47].
Several conditions that might effect gene expression
were examined in this study. Figure 1 reveals significant
increases in Cq between the disease groups for RPS19,
RPL8, B2M, HNRNPH, and GAPDH, The maximum
increase is seen in case of B2M between groups B and
D (0.51 Cq). These differences between the disease
groups can be contributed mainly to the disease condi-
tion as opposed to disease duration since the Cq was
not significantly different between the sequential sam-
ples taken during the disease period in a subset of the
dogs. The leukocyte count gradually increases compar-
ing the disease groups, revealing a significant difference
between group B (median leukocyte count 15.9*109/l)
versus C (median leukocyte count 16.8*109/l) and D
(median leukocyte count 22.6*109/l), respectively. The
changes in Cq associated with leukocyte count had a
similar direction as the Cq changes in the disease cate-
gories (Figure 1). This suggested that “leukocyte count”
might a major factor explaining the directional change
in Cq. The linear model examining the influence of “dis-
ease category” and “leukocyte count” revealed that this
was the case for RPS19 and RPL8. RPS5 and B2M were
best explained by the linear model containing both para-
meters, however. The reference genes that were not sig-
nificantly influenced by the WBC count were GUSB,
HNRNPH and SRPR (Table 3).
B2M has shown a highly variable expression in several
tissues other than whole blood [41,42,44,48] but had a
stable expression in one study where human leukocytes
from 13 healthy donors were examined [27]. B2M also
had stable expression in a large study where 526 human
whole blood samples representing healthy individuals
and 6 disease groups [49]. The influence of leukocyte
count on B2M expression was not examined in both
these studies. B2M encodes for beta-2-microglobulin
which is part of the canine MHC I molecule and abun-
dantly expressed on hematopoietic cells. The decrease in
B2M expression associated with increases in leukocyte
count in this study might reflect both a decrease in
induced expression, or a shift in leukocyte subsets dis-
playing different MHC class I receptor densities.
The selection of one, or a set of, potential reference
genes for a future experiment depends besides practical
points such as available sample sizes and costs mainly
on stability of expression in the experimental samples.
In this study we evaluated the expression stability with
Normfinder and GeNorm. Both software algorithms are
frequently used and freely available but have a different
working rationale. Normfinder selects out of a set of
potential reference genes one single, or the pair of, best
performing reference genes that show the least variation
between and within experimental groups. The focus on
the detection of directional changes in reference gene
expression due to differences between the experimental
groups is the major difference with GeNorm that
focuses on pair wise comparisons of reference gene
expression in the experimental samples and is therefore
less apt to identify coregulated genes [50]. Since WBC
count and disease category had a statistically significant
effect on potential reference gene expression, it is not
surprising that the ranking provided by Normfinder and
GeNorm differed. Among the genes ranked highest by
Normfinder were the genes that were not significantly
influenced by the WBC count (GUSB, HNRNPH and
SRPR, Table 3).
Contrastingly, GeNorm ranked RPS8, RPS19, and
RPS5 highest. Similarly, RPL8 had the best Stability
Value in Normfinder, but both RSP19 and RSP5 were
ranked at the low end of the list (Table 4). An explana-
tion might be that these three genes are all coding for
ribosomal proteins which are likely to be coregulated.
Despite the fact that they have less variation in expres-
sion as pointed out by GeNorm, the directional
Table 4 Ranking of potential reference genes according to their expression stability by GeNorm and Normfinder
GeNorm Stability measure* Normfinder Stability Value* Normfinder Stability Value*
M Disease category** WBC quartiles***
RPL8 and RPS19 0.55 RPL8 0.16 RPL8 0.09
HNRNPH 0.17 HNRNPH 0.14
RPS5 0.64 SRPR 0.19 GUSB 0.14
GUSB 0.78 GUSB 0.26 SRPR 0.16
B2M 0.87 HPRT 0.26 GAPDH 0.17
HNRNPH 0.93 RSP19 0.26 RSP19 0.17
HPRT 0.99 B2M 0.28 RPS5 0.21
GAPDH 1.01 RPS5 0.32 HPRT 0.21
SRPR 1.03 GAPDH 0.35 B2M 0.21
*Genes are ranked according to decreasing expression stability.
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difference in expression of these coregulated reference
genes, will potentially decrease the sensitivity of detect-
ing changes in expression of the genes of interest in an
experiment [51].
The discrepancy between the ranking of reference
genes in this study by Normfinder and Genorm can be
explained by differences between the experimental
groups such as “disease category” and “WBC count”.
These results reveal that experimental conditions can
result in unforeseen group wise up regulation or down
regulation of reference genes that otherwise may have a
stable expression when the whole dataset is considered.
Minor group specific directional changes in reference
gene expression might obscure changes in candidate
gene expression between groups. The results of this
study emphasize that it is prudent to assess each new
data set specifically for changes in reference gene
expression due to the experimental conditions even
when reference genes are chosen that were previously
shown to have a stable expression.
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